Trade Immunovant Inc - IMVT CFD

Immunovant, Inc. Company profile

About Immunovant Inc

Immunovant, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing treatments for patients with autoimmune diseases. The Company is developing IMVT-1401, a human anti-FcRn monoclonal antibody, as a subcutaneous injection for the treatment of autoimmune diseases mediated by pathogenic IgG antibodies. IMVT-1401 is being developed to target the neonatal Fc receptor (FcRn). It is also developing IMVT-1401 as a fixed-dose subcutaneous injection and focused initial development on the treatment of myasthenia gravis (MG), warm autoimmune hemolytic anemia (WAIHA), and thyroid eye disease (TED).

Financial summary

BRIEF: For the nine months ended 31 December 2021, Immunovant Inc revenues was not reported. Net loss increased 38% to $109.6M. Higher net loss reflects Research and development Bal increase of 33% to $61.2M (expense), General and administrative - Bala increase of 31% to $26.1M (expense), Stock-based Compensation in R&D increase from $4M to $8.6M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$0.95 to -$1.02.